PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission

Neuropsychopharmacology

Volumn 40, Issue 4, 2015, Pages 927-937

  De Guglielmo, Giordano ^a   Melis, Miriam ^b   De Luca, Maria Antonietta ^b,c   Kallupi, Marsida ^a   Li, Hong Wu ^a   Niswender, Kevin ^d,e   Giordano, Antonio ^f   Senzacqua, Martina ^f   Somaini, Lorenzo ^g   Cippitelli, Andrea ^a   Gaitanaris, George ^h   Demopulos, Gregory ^h   Damadzic, Ruslan ⁱ   Tapocik, Jenica ⁱ   Heilig, Markus ⁱ   Ciccocioppo, Roberto ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c National Institute of Neuroscience   (Italy)

^d Tennessee Valley Healthcare System   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g OSPEDALE DEGLI INFERMI   (Italy)

^h OMEROS CORPORATION   (United States)

ⁱ NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DIAMORPHINE; DOPAMINE; MORPHINE; OPIATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN DARPP 32; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTIDIABETIC AGENT; NARCOTIC AGENT;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; EX VIVO STUDY; EXCITATION; MESENCEPHALON; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; MICROINJECTION; MOTIVATION; MOUSE; NEOCORTEX; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REWARD; ROSTROMEDIAL TEGMENTAL NUCLEUS; TEGMENTUM; VENTRAL STRIATUM; ANIMAL; DRUG EFFECTS; DRUG SELF ADMINISTRATION; GENETICS; INSTRUMENTAL CONDITIONING; MALE; METABOLISM; PHYSIOLOGY; PREFRONTAL CORTEX; SYNAPTIC TRANSMISSION; TIME FACTOR; TRANSGENIC MOUSE; VENTRAL TEGMENTUM; WISTAR RAT;

ANILIDES; ANIMALS; CONDITIONING, OPERANT; DOPAMINE; DOPAMINERGIC NEURONS; GAMMA-AMINOBUTYRIC ACID; HEROIN; HYPOGLYCEMIC AGENTS; MALE; MICE, TRANSGENIC; MORPHINE; NARCOTICS; NUCLEUS ACCUMBENS; PPAR GAMMA; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SELF ADMINISTRATION; SYNAPTIC TRANSMISSION; THIAZOLIDINEDIONES; TIME FACTORS; VENTRAL TEGMENTAL AREA;

EID: 84925491248     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.268     Document Type: Article

References (52)

1. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28: 321-329.
2. Berger J, Moller DE (2002). The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
3. Bonci A, Williams JT (1996). A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 16: 631-639.
4. Bourdy R, Barrot M (2012). A new control center for dopaminergic systems: pulling the VTA by the tail. Trends Neurosci 35: 681-690.
5. Chieng B, Christie MJ (1994). Inhibition by opioids acting on mureceptors of GABAergic and glutamatergic postsynaptic potentials in single rat periaqueductal gray neurones in vitro. Br J Pharmacol 113: 303-309.
6. Compton WM, Volkow ND (2006). Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81: 103-107.
7. Di Chiara G (1995). The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38: 95-137.
8. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
9. Fibiger HC, LePiane FG, Jakubovic A, Phillips AG (1987). The role of dopamine in intracranial self-stimulation of the ventral tegmental area. J Neurosci 7: 3888-3896.
10. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A et al (1998). DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842.
11. Garzon M, Pickel VM (2001). Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area. Synapse 41: 311-328.
12. Gofflot F, Chartoire N, Vasseur L, Heikkinen S, Dembele D, Le Merrer J et al (2007). Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 131: 405-418.
13. Hjelmstad GO, Xia Y, Margolis EB, Fields HL (2013). Opioid modulation of ventral pallidal afferents to ventral tegmental area neurons. J Neurosci 33: 6454-6459.
14. Issemann I, Green S (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650.
15. Jalabert M, Bourdy R, Courtin J, Veinante P, Manzoni OJ, Barrot M et al (2011). Neuronal circuits underlying acute morphine action on dopamine neurons. Proc Natl Acad Sci USA 108: 16446-16450.
16. Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
17. Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA (2002). Generation and functional confirmation of a conditional null PPARgamma allele in mice. Genesis 32: 134-137.
18. Katz JL, Goldberg SR (1988). Preclinical assessment of abuse liability of drugs. Agents Actions 23: 18-26.
19. Kersten S, Desvergne B, Wahli W (2000). Roles of PPARs in health and disease. Nature 405: 421-424.
20. Lalwani ND, Reddy MK, Qureshi SA, Sirtori CR, Abiko Y, Reddy JK (1983). Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Hum Toxicol 2: 27-48.
21. Le Foll B, Di Ciano P, Panlilio LV, Goldberg SR, Ciccocioppo R (2013). Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. Curr Drug Targets 14: 768-776.
22. Lecca D, Valentini V, Cacciapaglia F, Acquas E, Di Chiara G (2007). Reciprocal effects of response contingent and noncontingent intravenous heroin on in vivo nucleus accumbens shell versus core dopamine in the rat: a repeated sampling microdialysis study. Psychopharmacology 194: 103-116.
23. Lecca S, Melis M, Luchicchi A, Ennas MG, Castelli MP, Muntoni AL et al (2011). Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. Neuropsychopharmacology 36: 589-602.
24. Lecca S, Melis M, Luchicchi A, Muntoni AL, Pistis M (2012). Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuropsychopharmacology 37: 1164-1176.
25. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S (2014). PPARgamma and the global map of adipogenesis and beyond. Trends Endocrinol Metab 25: 293-302.
26. Luscher C, Malenka RC (2011). Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69: 650-663.
27. Luscher C, Ungless MA (2006). The mechanistic classification of addictive drugs. PLoS Med 3: e437.
28. Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Hu Z et al (2009). Therapeutic targeting of 'DARPP-32': a key signaling molecule in the dopiminergic pathway for the treatment of opiate addiction. Int R Neurobiol 88: 199-222.
29. Margolis EB, Toy B, Himmels P, Morales M, Fields HL (2012). Identification of rat ventral tegmental area GABAergic neurons. PloS One 7: e42365.
30. Matsui A, Williams JT (2011). Opioid-sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons. J Neurosci 31: 17729-17735.
31. Melis M, Scheggi S, Carta G, Madeddu C, Lecca S, Luchicchi A et al (2013). PPARalpha regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving alpha7 nicotinic acetylcholine receptors. J Neurosci 33: 6203-6211.
32. Meye FJ, van Zessen R, Smidt MP, Adan RA, Ramakers GM (2012). Morphine withdrawal enhances constitutive mu-opioid receptor activity in the ventral tegmental area. J Neurosci 32: 16120-16128.
33. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ et al (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741.
34. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 13: CD001333.
35. Moreno S, Farioli-Vecchioli S, Ceru MP (2004). Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123: 131-145.
36. Nestler EJ (2005). Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.
37. Nishi A, Snyder GL, Greengard P (1997). Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17: 8147-8155.
38. Nutt DJ, King LA, Phillips LD (2010). Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558-1565.
39. Ouimet CC, Miller PE, Hemmings HC Jr., Walaas SI, Greengard P (1984). DARPP-32, a dopamine-and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 4: 111-124.
40. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Elsevier Academic Press, 2005.
41. Randall PA, Pardo M, Nunes EJ, Lopez Cruz L, Vemuri VK, Makriyannis A et al (2012). Dopaminergic modulation of effortrelated choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PloS One 7: e47934.
42. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD et al (2009). Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150: 707-712.
43. Schultz W (2002). Getting formal with dopamine and reward. Neuron 36: 241-263.
44. Segovia KN, Correa M, Lennington JB, Conover JC, Salamone JD (2012). Changes in nucleus accumbens and neostriatal c-Fos and DARPP-32 immunoreactivity during different stages of foodreinforced instrumental training. Eur J Neurosci 35: 1354-1367.
45. Stopponi S, de Guglielmo G, Somaini L, Cippitelli A, Cannella N, Kallupi M et al (2013). Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcohol Clin Exp Res 37: 1351-1360.
46. Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M et al (2011). Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcoholseeking. Biol Psychiatry 69: 642-649.
47. Svenningsson P, Nairn AC, Greengard P (2005). DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J 7: E353-E360.
48. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
49. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007). Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64: 1575-1579.
50. Wahli W, Michalik L (2012). PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 23: 351-363.
51. Wise RA (1996). Neurobiology of addiction. Curr Opin Neurobiol 6: 243-251.
52. Zachariou V, Sgambato-Faure V, Sasaki T, Svenningsson P, Berton O, Fienberg AA et al (2006). Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action. Neuropsychopharmacology 31: 555-562.